About Us

 

trenzyme's scientific expert in a lab - dedicated to delivering the ideal solution for you

trenzyme's company profile

trenzyme GmbH is a privately owned German Contract Research Organization (CRO) offering a wide range of highly customized services in cell line development, iPSC differentiation and recombinant protein production.

Since 2000, trenzyme has been a valued research partner of national and international clients, ranging from academia and small biotechs to big pharmaceutical companies. Our scientific experts are continuously developing new and comprehensive solutions to provide reliable, up-to-date support for the individual and demanding projects of our clients.

Whether your needs lie in the development of assay cell lines, production cell lines, cell expansion, differentiation of human induced pluripotent stem cells or in recombinant protein production, trenzyme’s team is dedicated to delivering the ideal solution for you. Get to know our team.

 

Your reliable research service provider

Learn more about our Highly Customized Cell & Protein Services

 

protein service iconHigh quality protein production and purification services according to your individual needs. Whether you are interested in conventional protein expression or in highly customized solutions for your demanding target, we are dedicated to providing the ideal solution for your research project.

Learn more

cell line service icon

Customized cell services tailored to your specific project requirements. Our highly skilled and experienced scientific experts provide a one-stop-shop from DNA to stable cell lines or GMP-compliant Research Cell Banks (RCB). In addition, we provide iPSC-related services compromising hiPSC banking, characterization and differentiation.

 

Your benefits from working with us


Proof of High Quality Made in Germany Symbol as proof of quick order process Another benefit from working with us: our high eypertise. Communication symbol - we will keep you constantly informed. Icon for our available customized services.

High Quality - Made in Germany

As an ISO-certified company working with a LIMS based documentation, all projects are completed following highest standards. Transparency and high quality service are our mission.

Quick Order


Find the protein or cell line you need in our catalog, order it and we will ship it to you within 2-5 business days, depending on destination.

 

Expertise


Since 2000, our highly qualified scientific experts employ their extensive experience to complete your project successfully and efficiently.

Communication


We will keep you constantly informed on the progress throughout the whole order and delivery process.

Customized Services Available

As a research provider, we offer a wide range of highly customized services for the development of cell lines, stem cell and the recombinant protein production.

Proof of High Quality Made in Germany Symbol as proof of quick order process Another benefit from working with us: our high eypertise.

High Quality - Made in Germany

As an ISO-certified company working with a LIMS based documentation, all projects are completed following highest standards. Transparency and hiqh quality service are our mission.

Quick Order


Find the protein or cell line you need in our catalog, order it and we will ship it to you within 2-5 business days, depending on destination.

 

Expertise


Since 2000, our highly qualified scientific experts employ their extensive experience to complete your project successfully and efficiently.

Communication symbol - we will keep you constantly informed. Icon for our available customized services.

Communication


We will keep you constantly informed on the progress troughout the whole order and delivery process.

Customized Services Available

As a research provider, we offer a wide range of highly customized services for the development of cell lines, stem cell and the recombinant protein production.

 

References

Citations

We've sold more than 300 catalog proteins since 2020. Some of our catalog proteins have been mentioned in publications. The references can be found in the table below. Have you cited one of our products in a publication? Let us know so we can reference it here.

 

Product SKU Citation Title Citation Authors Citation Date Citation Abstract Citation DOI
P2020-029 SARS-CoV-2 infects lung epithelial cells and induces senescence and an inflammatory response in patients with severe COVID-19 Konstantinos Evangelou, Dimitris Veroutis, Periklis G. Foukas, Koralia Paschalaki, Nefeli Lagopati, Marios Dimitriou, et al. 18 May 2021 Rationale SARS-CoV-2 infection of the respiratory system can progress to a life threatening multi-systemic disease, mediated via an excess of cytokines (“cytokine storm”), but the molecular mechanisms are poorly understood... read more https://doi.org/10.1101/2021.01.02.424917
P2020-001
P2020-100
Ultra-sensitive and fast optical detection of the spike protein of the SARS-CoV-2 using AgNPs/SiNWs nanohybrid based sensors Kais Daoudi, Krithikadevi Ramachandran, Hussain Alawadhi, Rabah Boukherroub, Elhadj Dogheche, et al. 15 September 2021 Severe acute respiratory syndrome SARS-CoV-2 virus led to notable challenges amongst researchers in view of development of new and fast detecting techniques. In this regard, surface-enhanced Raman spectroscopy (SERS) technique, providing a fingerprint characteristic for each material, would be an interesting approach. The current study encompasses ... read more https://doi.org/10.1016/j.surfin.2021.101454
P2020-031 SARS-CoV-2 S1 Protein Induces Endolysosome Dysfunction and Neuritic Dystrophy Gaurav Datta, Nicole M. Miller, Peter W. Halcrow, Nabab Khan, Timothy Colwell, Jonathan D. Geiger, Xuesong Chen 27 October 2021 SARS-CoV-2 is the viral cause of the COVID-19 pandemic. Increasingly, significant neurological disorders have been associated with COVID-19. However, the pathogenesis of these neurological disorders remains unclear especially because only low or undetectable levels of SARS-CoV-2 have been reported in human brain specimens. Because SARS-CoV-2 S1 protein can... read more https://doi.org/10.3389/fncel.2021.777738
P2020-001 Development and validation of novel kit for quantification of SARS-CoV-2 antibodies on clinical samples Sneha Kumari, Anoushka Raina, Dinesh Chandra, Nikita Gupta, Nikki Dey, et al. 17 December 2021 Since the pandemic occurred due to the emergence of SARS-CoV-2, there has always been a demand for a simple and sensitive diagnostic kit for detection of SARS-Cov-2 infection. In January 2020, WHO approved… read more https://doi.org/10.1016/j.jviromet.2021.114423
P2020-001 Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG Stephan Winklmeier, Katharina Eisenhut, Damla Taskin, Heike Rübsamen, Ramona Gerhards, Celine Schneider, et al. 20 December 2021 Although some COVID-19 patients maintain SARS-CoV-2-specific serum immunoglobulin G (IgG) for more than 6 months postinfection, others eventually lose IgG levels. We assessed the persistence of SARS-CoV-2-specific B cells in 17 patients, 5 of whom had lost specific IgGs after 5–8 months. Differentiation of blood-derived B cells ... read more https://doi.org/10.1016/j.isci.2021.103659
P2020-010 Quantitative measurement of IgG to SARS-CoV-2 antigens using monoclonal antibody-based enzyme-linked immunosorbent assays Ingrid Sander, Sabine Kespohl, Eva Zahradnik, Philipp Göcke, Ingolf Hosbach, Burkhard L Herrmann, Thomas Brüning, Monika Raulf 30 January 2022 Standardised quantitative analysis of the humoral immune response to SARS-CoV-2 antigens may be useful for estimating the extent and duration of immunity. The aim was to develop enzyme-linked immunosorbent assays (ELISAs) for the quantification of human IgG antibodies against... read more https://doi.org/10.1002/cti2.1369
P2020-025 Lactoferrin Binding to SARS-CoV-2 Spike Glycoprotein Blocks Pseudoviral Entry and Relieves Iron Protein Dysregulation in Several In Vitro Models Antimo Cutone, Luigi Rosa, Maria Carmela Bonaccorsi di Patti, Federico Iacovelli, Maria Pia Conte, Giusi Ianiro, Alice Romeo, et al. 3 October 2022 SARS-CoV-2 causes COVID-19, a predominantly pulmonary disease characterized by a burst of pro-inflammatory cytokines and an increase in free iron. The viral glycoprotein Spike mediates fusion to the host cell membrane, but its role as a virulence factor is largely unknown. Recently, the antiviral activity of lactoferrin against SARS-CoV-2 was demonstrated in vitro and ... read more https://doi.org/10.3390/pharmaceutics14102111
P2020-030 Increased circulating microparticles contribute to severe infection and adverse outcomes of COVID-19 in patients with diabetes Haoyu Sun, Yong Du, Rinki Kumar, Nicholas Buchkovich, and Pingnian He 21 November 2022 Patients with diabetes infected with COVID-19 have greater mortality than those without comorbidities, but the underlying mechanisms remain unknown. This study aims to identify the mechanistic interactions between diabetes and severe COVID-19. Microparticles (MPs), the cell membrane-derived vesicles released on cell activation, are largely increased in patients with ... read more https://doi.org/10.1152/ajpheart.00409.2022
P2020-022 High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection Eva-Maria Jacobsen, Dorit Fabricius, Magdalena Class, Fernando Topfstedt, Raquel Lorenzetti, Iga Janowska, et al. 28 November 2022 The COVID-19 course and immunity differ in children and adults. We analyzed immune response dynamics in 28 families up to 12 months after mild or asymptomatic infection. Unlike adults, the initial response is plasmablast-driven in children. Four months after infection, children show an enhanced specific antibody response and lower but detectable spike 1 protein (S1)-specific B and T cell ... read more https://doi.org/10.1038/s41467-022-35055-1
P2020-001 Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies Diana Isabel Sandoval Bojórquez, Željko Janićijević, Brenda Palestina Romero, Eduardo Sergio Oliveros Mata, Markus Laube, Anja Feldmann, et al. 10 February 2023 Detection of antigens and antibodies (Abs) is of great importance in determining the infection and immunity status of the population, as they are key parameters guiding the handling of pandemics. Current point-of-care (POC) devices are a convenient option for rapid screening; however, their sensitivity requires further improvement. We present an interdigitated gold nanowire-based impedance nanobiosensor to detect COVID-19-associated antigens (receptor-binding domain of S1 protein of the SARS-CoV-2 virus) and... read more https://doi.org/10.1021/acssensors.2c01686
P2020-001 Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region Marc Emmenegger, Elena De Cecco, David Lamparter, Raphaël P.B. Jacquat, Julien Riou, Dominik Menges et al. 17 February 2023 Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital ... read more https://doi.org/10.1016/j.isci.2023.105928
P2020-031
P2020-049
P2020-061
Veklury® (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether-β-cyclodextrin content Tamas Kovacs, Kitti Kurtan, Zoltan Varga, Peter Nagy, Gyorgy Panyi, Florina Zakany 27 February 2023 Despite its contradictory clinical performance, remdesivir (Veklury®) has a pivotal role in COVID-19 therapy. Possible contributions of the vehicle, sulfobutylether-β-cyclodextrin (SBECD) to Veklury® effects have been overlooked. The powder and ... read more https://doi.org/10.1111/bph.16063
P2020-001 Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice Reinhold Horlacher, Armin Günther, Alexander Brosig, Jenny Morath, Barbara Jakobs, Marcus Groettrup, et al. 21 March 2023 SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variants of the virus. This may ultimately only be possible through induction of potent and long-lasting immune... read more https://doi.org/10.1038/s41598-023-31198-3
P2020-031 Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals Joana Barros-Martins, Swantje I. Hammerschmidt, Gema Morillas Ramos, Anne Cossmann, Laura Hetzel, Ivan Odak, et al. 5 May 2023 Since early 2022, various Omicron variants have dominated the SARS-CoV-2 pandemic in most countries. All Omicron variants are B-cell immune escape variants, and antibodies induced by first-generation COVID-19 vaccines or by infection with earlier SARS-CoV-2 variants largely fail to protect individuals from Omicron infection. In the present study, we investigated the effect of Omicron infections in triple-vaccinated and in antigen-naive individuals. We show that Omicron breakthrough infections occurring... read more https://doi.org/10.3389/fimmu.2023.1166589
P2020-060 A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells Alexandra Kegler, Laura Drewitz, Claudia Arndt, Cansu Daglar, Liliana Rodrigues Loureiro, et al. 13 June 2023 The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence... read more https://doi.org/10.3389/fimmu.2023.1204543